For research use only. Not for therapeutic Use.
Cenicriviroc mesylate（Cat No.:I012935）is a novel, orally administered dual CCR2/CCR5 antagonist, primarily investigated for the treatment of HIV and inflammatory conditions. By blocking the CCR2 and CCR5 chemokine receptors, it disrupts the pathways that allow HIV entry into host cells and modulates immune responses. This dual action not only helps in reducing viral load but also addresses inflammation, making it a potential candidate for managing conditions such as non-alcoholic steatohepatitis (NASH). Cenicriviroc mesylate’s safety and efficacy profile is being evaluated in clinical trials, highlighting its promise in antiviral and anti-inflammatory therapies.
| Catalog Number | I012935 |
| CAS Number | 497223-28-6 |
| Molecular Formula | C₄₂H₅₆N₄O₇S₂ |
| Purity | ≥95% |
| Target | CCR |
| Solubility | DMSO |
| IUPAC Name | (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide;methanesulfonic acid |
| InChI | InChI=1S/C41H52N4O4S.CH4O3S/c1-5-7-22-48-23-24-49-38-15-10-32(11-16-38)33-12-19-40-35(25-33)26-34(9-8-21-44(40)28-31(3)4)41(46)43-36-13-17-39(18-14-36)50(47)29-37-27-42-30-45(37)20-6-2;1-5(2,3)4/h10-19,25-27,30-31H,5-9,20-24,28-29H2,1-4H3,(H,43,46);1H3,(H,2,3,4)/b34-26+;/t50-;/m0./s1 |
| InChIKey | IXPBPUPDRDCRSY-YLZLUMLXSA-N |
| SMILES | CCCCOCCOC1=CC=C(C=C1)C2=CC/3=C(C=C2)N(CCC/C(=C3)/C(=O)NC4=CC=C(C=C4)[S@@](=O)CC5=CN=CN5CCC)CC(C)C.CS(=O)(=O)O |
| Reference | [1]. Lefebvre E, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016 Jun 27;11(6):e0158156. <br>[2]. Visseaux B, et al. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One. 2015 Aug 6;10(8):e0134904. |
